Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | RxPONDER: sparing chemotherapy in node-positive early-stage breast cancer

Bora Lim • 14 Dec 2020
SABCS 2020
Breast Cancer
RxPONDER

Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses some key updates presented at this year’s virtual San Antonio Breast Cancer Symposium including the RxPONDER study which evaluated whether chemotherapy could be spared in women with node-positive early-stage breast cancer based on OncoType Dx ® score. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Bora Lim

1:32
Highlights at SABCS 2021 for basic science and early-phase clinical trials
Bora Lim • 9 Dec 2021
1:48
Single-cell genomics and proteogenomics in cancer
Bora Lim • 9 Dec 2021
1:40
Advances in the management of inflammatory breast cancer
Bora Lim • 9 Dec 2021
1:32
Treatment algorithm for TNBC
Bora Lim • 9 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals